184 related articles for article (PubMed ID: 37410453)
1. Recent advances in anaplastic thyroid cancer management.
Hamidi S; Maniakas A
Curr Opin Endocrinol Diabetes Obes; 2023 Oct; 30(5):259-264. PubMed ID: 37410453
[TBL] [Abstract][Full Text] [Related]
2. Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in
Wang JR; Zafereo ME; Dadu R; Ferrarotto R; Busaidy NL; Lu C; Ahmed S; Gule-Monroe MK; Williams MD; Sturgis EM; Goepfert RP; Gross ND; Lai SY; Gunn GB; Phan J; Rosenthal DI; Fuller CD; Morrison WH; Iyer P; Cabanillas ME
Thyroid; 2019 Aug; 29(8):1036-1043. PubMed ID: 31319771
[No Abstract] [Full Text] [Related]
3. Advances in the management of anaplastic thyroid carcinoma: transforming a life-threatening condition into a potentially treatable disease.
Califano I; Smulever A; Jerkovich F; Pitoia F
Rev Endocr Metab Disord; 2024 Feb; 25(1):123-147. PubMed ID: 37648897
[TBL] [Abstract][Full Text] [Related]
4. Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases.
Xu B; Fuchs T; Dogan S; Landa I; Katabi N; Fagin JA; Tuttle RM; Sherman E; Gill AJ; Ghossein R
Thyroid; 2020 Oct; 30(10):1505-1517. PubMed ID: 32284020
[No Abstract] [Full Text] [Related]
5. Combination
Gunda V; Ghosh C; Hu J; Zhang L; Zhang YQ; Shen M; Kebebew E
Thyroid; 2023 Oct; 33(10):1201-1214. PubMed ID: 37675898
[No Abstract] [Full Text] [Related]
6. Current picture of anaplastic thyroid cancer patients' care and meetable needs: A survey of 94 Institutions from the EORTC Endocrine and Head and Neck Cancer Groups.
Locati LD; Colombo E; Dedecjus M; de la Fouchardière C; Sents W; Bongiovanni M; Netea-Maier R
Eur J Cancer; 2023 Feb; 180():146-154. PubMed ID: 36599182
[TBL] [Abstract][Full Text] [Related]
7. Case report: Complete response of an anaplastic thyroid carcinoma patient with
Gui L; Zhu Y; Li X; He X; Ma T; Cai Y; Liu S
Front Immunol; 2023; 14():1178682. PubMed ID: 37122752
[TBL] [Abstract][Full Text] [Related]
8. Genomic Alterations of Anaplastic Thyroid Carcinoma Detected by Targeted Massive Parallel Sequencing in a BRAF(V600E) Mutation-Prevalent Area.
Jeon MJ; Chun SM; Kim D; Kwon H; Jang EK; Kim TY; Kim WB; Shong YK; Jang SJ; Song DE; Kim WG
Thyroid; 2016 May; 26(5):683-90. PubMed ID: 26980298
[TBL] [Abstract][Full Text] [Related]
9. Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma.
Qin Y; Wang JR; Wang Y; Iyer P; Cote GJ; Busaidy NL; Dadu R; Zafereo M; Williams MD; Ferrarotto R; Gunn GB; Wei P; Patel K; Hofmann MC; Cabanillas ME
Thyroid; 2021 Aug; 31(8):1235-1243. PubMed ID: 33599171
[No Abstract] [Full Text] [Related]
10. Real-Time Genomic Characterization Utilizing Circulating Cell-Free DNA in Patients with Anaplastic Thyroid Carcinoma.
Sandulache VC; Williams MD; Lai SY; Lu C; William WN; Busaidy NL; Cote GJ; Singh RR; Luthra R; Cabanillas ME
Thyroid; 2017 Jan; 27(1):81-87. PubMed ID: 27785980
[TBL] [Abstract][Full Text] [Related]
11. Mutation based approaches to the treatment of anaplastic thyroid cancer.
McCrary HC; Aoki J; Huang Y; Chadwick B; Kerrigan K; Witt B; Hunt JP; Abraham D
Clin Endocrinol (Oxf); 2022 May; 96(5):734-742. PubMed ID: 35067961
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 expression in rare and aggressive thyroid cancers: A preliminary investigation for a role of immunotherapy.
Boruah M; Gaddam P; Agarwal S; Mir RA; Gupta R; Sharma MC; S Deo SV; Nilima N
J Cancer Res Ther; 2023; 19(2):312-320. PubMed ID: 37006068
[TBL] [Abstract][Full Text] [Related]
13. Histological features of BRAF V600E-mutant anaplastic thyroid carcinoma.
Chen TY; Lorch JH; Wong KS; Barletta JA
Histopathology; 2020 Aug; 77(2):314-320. PubMed ID: 32428249
[TBL] [Abstract][Full Text] [Related]
14. Dabrafenib and Trametinib Therapy for Advanced Anaplastic Thyroid Cancer - Real-World Outcomes From UK Centres.
Lorimer C; Cheng L; Chandler R; Garcez K; Gill V; Graham K; Grant W; Sardo Infirri S; Wadsley J; Wall L; Webber N; Wong KH; Newbold K
Clin Oncol (R Coll Radiol); 2023 Jan; 35(1):e60-e66. PubMed ID: 36379836
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant BRAF- and Immune-Directed Therapy for Anaplastic Thyroid Carcinoma.
Cabanillas ME; Ferrarotto R; Garden AS; Ahmed S; Busaidy NL; Dadu R; Williams MD; Skinner H; Gunn GB; Grosu H; Iyer P; Hofmann MC; Zafereo M
Thyroid; 2018 Jul; 28(7):945-951. PubMed ID: 29742974
[TBL] [Abstract][Full Text] [Related]
16. Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis.
Charles RP; Silva J; Iezza G; Phillips WA; McMahon M
Mol Cancer Res; 2014 Jul; 12(7):979-86. PubMed ID: 24770869
[TBL] [Abstract][Full Text] [Related]
17. Anaplastic thyroid cancer:Improved understanding of what remains a deadly disease.
Cleere EF; Prunty S; O'Neill JP
Surgeon; 2024 Feb; 22(1):e48-e53. PubMed ID: 37866980
[TBL] [Abstract][Full Text] [Related]
18. Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAF
Zhao X; Wang JR; Dadu R; Busaidy NL; Xu L; Learned KO; Chasen NN; Vu T; Maniakas A; Eguia AA; Diersing J; Gross ND; Goepfert R; Lai SY; Hofmann MC; Ferrarotto R; Lu C; Gunn GB; Spiotto MT; Subbiah V; Williams MD; Cabanillas ME; Zafereo ME
Thyroid; 2023 Apr; 33(4):484-491. PubMed ID: 36762947
[No Abstract] [Full Text] [Related]
19. [Molecular diagnostics enable targeted therapies for anaplastic and poorly differentiated thyroid cancer].
Altena R; Nilsson M; Bergman V; Dahlberg J; Christofer Juhlin C; Zedenius J
Lakartidningen; 2024 Feb; 121():. PubMed ID: 38712675
[TBL] [Abstract][Full Text] [Related]
20. Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations.
Smith N; Nucera C
J Clin Endocrinol Metab; 2015 Jan; 100(1):35-42. PubMed ID: 25347569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]